Match!
Akihito Kubo
Aichi Medical University
122Publications
20H-index
1,289Citations
Publications 124
Newest
#1Ikuto Tsukiyama (Aichi Medical University)H-Index: 4
#2Masahiko Ando (Nagoya University)H-Index: 41
Last.Akihito Kubo (Aichi Medical University)H-Index: 20
view all 11 authors...
Purpose Neurokinin-1 receptor antagonist (NK1RA) is recommended to prevent chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly or moderately emetogenic chemotherapy (HEC or MEC, respectively). We previously reported that aprepitant, an NK1RA, was needed to control CINV in 43% and 12% of patients who received HEC and MEC, respectively (Support Care Cancer 23:905–912, 2015). To elucidate the cost-effectiveness of aprepitant in these patients, a cost-utility analysis acco...
Source
#1Kazuhisa TakahashiH-Index: 7
#2Kazuhisa TakahashiH-Index: 58
Last.Toyoaki HidaH-Index: 43
view all 15 authors...
Source
#2Kentaro ItoH-Index: 4
Last.Noboru Yamamoto (Wakayama Medical University)H-Index: 55
view all 20 authors...
Abstract Background Previous clinical trials demonstrated that alectinib (ALEC) produced fewer adverse events compared to crizotinib (CRZ). Data regarding adverse events (AE) in clinical practice, however, is limited. We reviewed ALK-rearranged NSCLC patients treated with crizotinib or alectinib in institutions of the West Japan Oncology Group, and the safety of CRZ and ALEC were evaluated using the real-world data. Methods We reviewed the clinical data of ALK-rearranged NSCLC patients who recei...
Source
#2Ryoji Kato (Kindai University)H-Index: 5
Last.Kazuo NakagawaH-Index: 23
view all 20 authors...
Source
e20017Background: P has widely been used for the risk assessment of lung cancer and chronic obstructive pulmonary disease (COPD). We previously reported that mutations in KRAS, TP53, and EGFR were ...
#1Toshio Kato (Aichi Medical University)
#2Satoru Ito (Aichi Medical University)
Last.Etsuro Yamaguchi (Aichi Medical University)H-Index: 28
view all 6 authors...
Source
#1Nobuhiro Asai (Aichi Medical University)H-Index: 7
#2Akihito Kubo (Aichi Medical University)H-Index: 20
Last.Etsuro Yamaguchi (Aichi Medical University)H-Index: 28
view all 8 authors...
AbstractTo clarify the prognostic impact of tumor-infiltrating effector regulatory T cells (eTregs) in non-small cell lung cancer (NSCLC), eTregs were evaluated by immunohistochemical detection of CCR4 and Foxp3 in 108 consecutive surgical NSCLC tumors. Multivariate analysis showed that a high ratio of CCR4+ eTregs to total Tregs (≥40%) was the only independent risk factor for relapse-free survival (odds ratio [OR]: 6.54, 95% confidence interval: 1.67–25.7, p = .007) and overall survival (OR: 3....
2 CitationsSource
#1Ayumu Takahashi (Aichi Medical University)H-Index: 8
#2Akihito Kubo (Aichi Medical University)H-Index: 20
Last.Etsuro Yamaguchi (Aichi Medical University)H-Index: 28
view all 13 authors...
1 CitationsSource
#1Teppei Yamaguchi (Fujita Health University)H-Index: 3
#2S. Morikawa (Fujita Health University)
Last.Kazuyoshi Imaizumi (Fujita Health University)H-Index: 10
view all 17 authors...
Source
#2Tatsuya Yoshida (NYU: New York University)H-Index: 7
Last.Toyoaki HidaH-Index: 43
view all 16 authors...
Source
12345678910